Complete and rapid response to FOLFIRI plus bevacizumab in a patient presenting with impaired liver function and poor performance status from colon cancer liver metastases.
Impaired liver function is a final complication of hepatic metastases from colon cancer. This disease status is of critical importance at first clinical presentation because of the tight therapeutic window for chemotherapy. A rapid response to treatment is required as other means of supportive care for hepatic function are limited. New targeted therapies including monoclonal antibodies directed against several proteins with key roles in colon cancer biology are now available, allowing new treatment options for this group of patients. Here, we present a patient with highly impaired liver function secondary to hepatic metastases from colon cancer that showed clinical and radiological improvement after systemic treatment including bevacizumab.
aMedical Oncology Division, University Hospital La Paz, School of Medicine, Autonomous University of Madrid, Madrid bMD Anderson Cancer Center International, Madrid, Spain.
Cristóbal
C
Belda-Iniesta
Enrique Casado
EC
Sáenz
Javier
J
de Castro-Carpeño
Elena
E
Hernández
Manuel González
MG
Barón